Prostate cancer is primarily detected using serum levels of kallikrein-related peptidase 3 (KLK3, prostate-specific antigen, PSA), which is the established biomarker for diagnosis and prognosis [2]. This evidence concerns the gene KLK3 and prostate carcinoma.